Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours

被引：0
|
作者：
Bodei, L. [1 ]
Cremonesi, M. [1 ]
Grana, C. [1 ]
Bartolomei, M. [1 ]
Baio, S. [1 ]
Bufi, G. [1 ]
Fiorenza, M. [1 ]
Obenaus, E. [1 ]
Paganelli, G. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S214 / S214
页数：1
相关论文
共 50 条
  • [41] Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
    Anna Sundlöv
    Katarina Sjögreen-Gleisner
    Johanna Svensson
    Michael Ljungberg
    Tomas Olsson
    Peter Bernhardt
    Jan Tennvall
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1480 - 1489
  • [42] 177Lu-DOTATATE receptor radionuclide therapy: Internal dosimetry estimates and considerations for practical protocols
    Cremonesi, Marta
    Di Dia, Giuseppina Amalia
    Bodei, Lisa
    Botta, Francesca
    Ferrari, Mahila
    De Cicco, Concetta
    Prisco, Gennaro
    Pedroli, Guido
    Paganelli, Giovanni
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [43] Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska, Jolanta
    Krolicki, Leszek
    Hubalewska-Dydejczyk, Alicja
    Mikolajczak, Renata
    Sowa-Staszczak, Anna
    Pawlak, Dariusz
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (10) : 1788 - 1797
  • [44] Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Jolanta Kunikowska
    Leszek Królicki
    Alicja Hubalewska-Dydejczyk
    Renata Mikołajczak
    Anna Sowa-Staszczak
    Dariusz Pawlak
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 1788 - 1797
  • [45] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
  • [46] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
    Marin, G.
    Vanderlinden, B.
    Wimana, Z.
    Guiot, T.
    Karfis, I.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
  • [47] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [48] Assessing neuroendocrine tumour response to peptide receptor radionuclide therapy with 177Lu-DOTATATE using voxel-based dosimetry
    Ram, L.
    Bissell, S.
    Hughes, S.
    Ross, E.
    Geh, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S395 - S395
  • [49] Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Minczeles, Noemie S.
    de Herder, Wouter W.
    Feelders, Richard A.
    Verburg, Frederik A.
    Hofland, Johannes
    Brabander, Tessa
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 40 - 46
  • [50] Lutetium-177 Dotatate peptide receptor radionuclide therapy outcomes for neuroendocrine tumours
    AlHilali, M.
    Carberry, J.
    Challis, A.
    Atherton, P.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1095 - S1096
12345